When does entyvio patent expire?

Entyvio (vedolizumab) patent status – a quick snapshot

What does that mean for Entyvio’s patent protection?

In short:

• The core patents covering the vedolizumab molecule itself and its primary use in ulcerative colitis and Crohn’s disease have already expired (most by 2021–2024 in the U.S.).
• Certain formulation, delivery, and manufacturing‑process patents remain in force and will continue to protect Entyvio’s market position until roughly 2024–2028 in the U.S. (and similar timelines in other jurisdictions, though exact dates vary by country).
• After those process patents lapse, generic manufacturers could begin developing biosimilar versions, but they still must satisfy regulatory standards (e.g., FDA’s “biosimilar” pathway).

Why this matters

• Generic competition: When all relevant patents expire, third‑party manufacturers can seek approval to market biosimilar versions, which can lower costs for patients and payers.
• Patent strategy: Biologics often rely on process patents (e.g., cell lines, purification steps) to extend exclusivity beyond the 20‑year rule for the active ingredient. This is why you see patents extending into the 2028–2030 range even after the core molecule’s patents have expired.

Quick takeaway

• Core composition and use patents: Expired (by 2021–2024).
• Formulation/process patents: Remain active until 2024–2028 (U.S.), with some process patents extending to 2036.

If you’re planning a biosimilar development or simply want to know when generic competition is likely, keep an eye on the specific process patents that still apply to Entyvio’s manufacturing and delivery.